Skip to main content
$199.79 -$0.71 (-0.4%)

01:33 PM EDT on 07/26/21

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX)

CAPS Rating: 4 out of 5

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.

Current Price $199.79 Mkt Cap $51.9B
Open $199.43 P/E Ratio 18.85
Prev. Close $0.00 Div. (Yield) $0.00 (0.0%)
Daily Range $199.16 - $202.41 Volume 2,466,669
52-Wk Range $185.33 - $285.57 Avg. Daily Vol. 2,660,793

Caps

How do you think NASDAQ:VRTX will perform against the market?

Add Stock to CAPS Watchlist

All Players

824 Outperform
70 Underperform
 

All-Star Players

197 Outperform
11 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:VRTX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

CMFJoeFoolery (< 20)
Submitted April 05, 2021

-Bullishness on gene therapy segment and partnership w/ CRISPR-Strength in Cystic Fibrosis treatment (Dominant, but large part of US TAM left to capture)-Research methodology/product development strategy-Current valuation and multiples. ($55Bn,… More

SCOTTRHUETTLCPA (39.13)
Submitted July 22, 2016

9/26/14 DOWN TO UP = <30.04> 7/19/16 = UP TO DOWN

NASDAQ:VRTX VS S&P 500 (SPY)

Fools bullish on NASDAQ:VRTX are also bullish on:

Fools bearish on NASDAQ:VRTX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about VRTX.

Recs

0
Member Avatar TMFRetireFoolish (26.76) Submitted: 7/17/2021 11:04:18 AM : Outperform Start Price: $200.60 NASDAQ:VRTX Score: -3.05

Highly profitable cystic fibrosis franchise generating $3 billion in FCF and funding investments for next blockbuster

Recs

0
Member Avatar TMFjbonefish (56.60) Submitted: 7/13/2021 5:16:56 PM : Outperform Start Price: $197.51 NASDAQ:VRTX Score: +1.17

It owns cystic fibrosis and is partnering to develop a next-generation gene therapy. It may lag in the near term, but the cash cow should allow it develop or acquire strategic assets that drive growth. In the meantime, it's cheap.

Recs

1
Member Avatar CMFJoeFoolery (< 20) Submitted: 4/5/2021 4:38:48 PM : Outperform Start Price: $215.50 NASDAQ:VRTX Score: -15.18

-Bullishness on gene therapy segment and partnership w/ CRISPR
-Strength in Cystic Fibrosis treatment (Dominant, but large part of US TAM left to capture)
-Research methodology/product development strategy
-Current valuation and multiples. ($55Bn, attractive growth in revenue and net income the past few yrs, plenty of cash on hand)

Leaderboard

Find the members with the highest scoring picks in VRTX.

Score Leader

bugeyebear

bugeyebear (36.57) Score: +1,017.70

The Score Leader is the player with the highest score across all their picks in VRTX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
bugeyebear 36.57 3/17/2008 Outperform 3Y $14.60 +1,277.02% +259.32% +1,017.70 0 Comment
lostontheprairie 67.87 3/12/2008 Outperform 5Y $14.99 +1,241.19% +245.56% +995.64 0 Comment
Kudude 63.44 3/12/2008 Outperform 5Y $14.99 +1,241.19% +245.56% +995.64 0 Comment
Salilp 73.14 3/17/2008 Outperform 5Y $15.07 +1,234.07% +262.39% +971.69 0 Comment
davidmouw2 < 20 3/14/2008 Outperform NS $15.43 +1,202.95% +245.46% +957.49 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. snazzysnazz 71.31 3/13/2008 Outperform 5Y $15.49 +1,197.90% +253.90% +944.00 0 Comment
NovaMechanika 21.25 3/20/2008 Outperform 3Y $15.55 +1,192.89% +250.97% +941.93 2 Comments
stnewbie 37.74 3/12/2008 Outperform NS $15.78 +1,174.05% +247.13% +926.92 0 Comment
PrincetonAl 86.24 3/7/2008 Outperform 3Y $15.86 +1,167.62% +253.84% +913.78 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. hayrettin 72.19 3/24/2008 Outperform 5Y $16.47 +1,120.67% +242.37% +878.30 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for VRTX.